Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9206133 | 0.87 | GFER (0.36) | ESR1ESR2CA2TAAR1KMT2A | |
| SCHEMBL5610502 | 0.86 | ESR1 (0.54) | ESR1ESR2CA2KDM4EALDH1A1 | |
| SCHEMBL6886212 | 0.85 | ESR1 (0.53) | ESR1ESR2CA2KDM4EALDH1A1 | |
| SCHEMBL440374 | 0.76 | TAAR1 (0.50) | KDM4EALDH1A1CYP2C19HTR3ATAAR1 | |
| SCHEMBL910881 | 0.76 | CA2 (0.47) | ESR1ESR2CA2KDM4EALDH1A1 | |
| SCHEMBL8439000 | 0.76 | HRH3 (0.46) | CA2TAAR1ABAT | |
| SCHEMBL980506 | 0.76 | TAAR1 (0.50) | TAAR1MIFPTGS1PTGS2 | |
| SCHEMBL98012 | 0.76 | TAAR1 (0.50) | TAAR1 | |
| SCHEMBL450038 | 0.76 | ESR1 (0.59) | ESR1ESR2CA2KDM4EALDH1A1 | |
| SCHEMBL692408 | 0.76 | GFER (0.59) | CA2ALDH1A1KMT2ATDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| CN-113491703-A | Application of phenylethanoid glycosides compounds and compositions thereof in preparation of drugs for preventing and treating new coronary pneumonia | 中国科学院上海药物研究所 | 2021-10-12 | — | — | CN | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | claimed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | claimed |
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-02-21 | — | — | US | claimed |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2012-11-01 | — | — | US | claimed |
| EP-2511283-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2012-10-17 | — | — | EP | claimed |
| US-20120214994-A1 | (3-FLUORO-2-HYDROXY)PROPYL-FUNCTIONALIZED ARYL DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR THE DIAGNOSIS OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASES | FUTURECHEM CO., LTD. (KR) | 2012-08-23 | — | — | US | claimed |
| EP-0443559-A2 | HIV protease inhibiting agents | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-08-28 | — | — | EP | claimed |
| EP-0411332-A1 | Antiviral peptides having a 2-oxoalkyl amino acid side chain | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-02-06 | — | — | EP | claimed |
| EP-0408973-A1 | Antiherpes pentapeptides | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-01-23 | — | — | EP | claimed |
| US-4686283-A | POLYPEPTIDES | SYNTEX (U.S.A.) INC. (US) | 1987-08-11 | — | — | US | claimed |
| US-4638046-A | Retro-inverso C-terminal hexapeptide analogues of substance P | ENI-ENTE NAZIONALE IDROCARBURI (IT) | 1987-01-20 | — | — | US | claimed |
| EP-0161007-A2 | Retro - inverso C-Terminal hexapeptide analogues of substance P | ENI-Ente Nazionale Idrocarburi (IT) | 1985-11-13 | — | — | EP | claimed |
| EP-0082568-B1 | RETRO-INVERSO ANALOGUES OF C-TERMINAL PENTA AND HEXAPEPTIDES OF SUBSTANCE P. | ANIC S.p.A. (IT) | 1984-11-21 | — | — | EP | claimed |
| US-4439360-A | Retro-inverso analogues of C-terminal penta and hexapeptides of Substance P | ANIC S.P.A. (IT) | 1984-03-27 | — | — | US | claimed |
| EP-0082568-A2 | Retro-inverso analogues of C-terminal penta and hexapeptides of substance P. | ANIC S.p.A. (IT) | 1983-06-29 | — | — | EP | claimed |
| US-4057618-A | IMAGING AGENT FOR BODY TISSUES | UNIVERSITY PATENTS, INC. (US) | 1977-11-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | ESR1 1524/4885ESR2 409/4885CA2 765/4885 |
| US-20120214994-A1 | (3-FLUORO-2-HYDROXY)PROPYL-FUNCTIONALIZED ARYL DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR THE DIAGNOSIS OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASES | APP, FABP7, SLC3A2 | ESR1 3732/4885ESR2 2958/4885CA2 1695/4885 |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | ESR1 3129/4885ESR2 3549/4885CA2 2204/4885 |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | ESR1 3129/4885ESR2 3549/4885CA2 2204/4885 |
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | ADORA2A, ADORA3, ADORA1 | ESR1 2260/4885ESR2 3107/4885CA2 3762/4885 |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | DDB1, CCL2, DDIT3 | ESR1 3378/4885ESR2 2174/4885CA2 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.